NUVB 250117 7.50C (NUVB250117C7500) Stock Options, News & Quotes

US OptionsDetailed Quotes

NUVB250117C7500

Watchlist

0.05
0.000.00%

15min DelayClose Jan 17 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

Nuvation Bio Up Nearly 17%, on Track for Largest Percent Increase Since March 2024 -- Data Talk
Dow JonesJan 7 15:12 ET
UniFirst, Getty Images, Shutterstock And Other Big Stocks Moving Higher On Tuesday
BenzingaJan 7 10:15 ET
RBC Capital Maintains Nuvation Bio(NUVB.US) With Buy Rating, Raises Target Price to $10
Moomoo NewsJan 7 07:36 ET · Ratings
Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BusinesswireJan 6 16:05 ET
Express News | Nuvation Bio Inc - Taletrectinib to Be Marketed in China by Innovent Biologics
ReutersJan 6 08:00 ET
Express News | HC Wainwright & Co. Reiterates Buy on Nuvation Bio, Maintains $7 Price Target
BenzingaJan 6 06:45 ET

Comments

flabbyduck

Dec 23, 2024 07:05

nice one (: small but sweet.
$Nuvation Bio (NUVB.US)$

Share Your Profit/Loss

Trytosaveabit

Dec 23, 2024 07:01

Update

$Nuvation Bio (NUVB.US)$ Reuters· just1min
U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced Ros1-Positive Non-Small Cell Lung Cancer! June 23, 2025

Jaguar8

Sep 15, 2024 19:34

WEEKEND NEWS

$Nuvation Bio (NUVB.US)$
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024
Nuvation Bio (NYSE: NUVB) announced positive pooled data from TRUST-I and TRUST-II studies evaluating taletrectinib, a next-generation ROS1 TKI for advanced ROS1-positive NSCLC. Key findings include:
- 89% tumor shr...

Clintzilla

Sep 15, 2024 08:02

$Nuvation Bio (NUVB.US)$ big arse float but on watch

Trytosaveabit

Jun 26, 2024 16:16

Insider buy! Or should I say MORE buys! Hehehe

$Nuvation Bio (NUVB.US)$ Director Cui Xiangmin purchased 277.9K shares of common stock on Jun 25, 2024 at an average price of $2.97 for a total value of $825.35K.